

Emerson A Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1086049/publications.pdf>

Version: 2024-02-01

21
papers

279
citations

933447

10
h-index

940533

16
g-index

22
all docs

22
docs citations

22
times ranked

507
citing authors

#	ARTICLE	IF	CITATIONS
1	¿Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2015, 115, 709-723.e3.	0.8	51
2	Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. <i>Radiology</i> , 2018, 287, 778-786.	7.3	39
3	Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¿Cocinar Para Su Salud! Randomized Controlled Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1491-1502.	2.5	33
4	¿Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2015, 115, S42-S56.e3.	0.8	27
5	Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 718-721.	1.9	19
6	Telemedicine in management of genitourinary malignancies: Patient and physician perspectives. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 480-486.	1.6	18
7	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. <i>Clinical Cancer Research</i> , 2022, 28, 1285-1293.	7.0	16
8	Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 533-540.	2.5	15
9	Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy. <i>Bladder Cancer</i> , 2017, 3, 181-189.	0.4	14
10	Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2507-2507.	1.6	12
11	Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 279-279.	1.6	8
12	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. <i>Prostate</i> , 2020, 80, 336-344.	2.3	7
13	Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. <i>Journal of Clinical Oncology</i> , 2017, 35, 327-327.	1.6	5
14	A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5082-5082.	1.6	3
15	The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS373-TPS373.	1.6	2
16	Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5025-5025.	1.6	2
17	Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 205-205.	1.6	1
18	Diffusion of abiraterone use in prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18062-e18062.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Renal Cell Cancer Treated with a Single-Edged Sword. Cell Reports, 2013, 3, 275-276.	6.4	0
20	Ethnic differences in tumor proliferation in women with early-stage breast cancer.. Journal of Clinical Oncology, 2013, 31, 560-560.	1.6	0
21	CTNI-49. PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN β , IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MULTIFORME. Neuro-Oncology, 2021, 23, vi71-vi71.	1.2	0